RxDoctor Payments Data

Zulmari Campos, MD

Pulmonary Disease · Cayey, PRNPI 1689843328

Payments from drug & device makers

$1,194in general payments, 2019–2025

Across 48 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$338
  • Boehringer Ingelheim$333
  • Sanofi$164
  • AstraZeneca$138
  • Mallinckrodt Hospital Products Inc.$100
  • Genentech USA, Inc.$46
  • plus $74 from 3 others

What the payments were for

  • Food & beverage$1,09492%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK15$338
Boehringer Ingelheim21$333
Sanofi2$164
AstraZeneca3$138
Mallinckrodt Hospital Products Inc.1$100
Genentech USA, Inc.2$46
Pfizer Pharmaceuticals LLC2$35
Johnson & Johnson1$25
Mylan Specialty L.p.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,194 in reported general payments places this provider in the 25th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,883
Medicare patients
15
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter444$295,831
Stiolto RespimatTiotropium Br/Olodaterol Hcl409$200,695
Arnuity ElliptaFluticasone Furoate607$160,776
Spiriva RespimatTiotropium Bromide257$137,088
Dupixent PenDupilumab24$91,652
Wixela InhubFluticasone Propion/Salmeterol162$35,822
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr74$35,549
Albuterol Sulfate HfaAlbuterol Sulfate663$30,626
Fluticasone-SalmeterolFluticasone Propion/Salmeterol221$26,911
Atrovent HfaIpratropium Bromide53$25,266
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate68$18,933
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$18,926
SymbicortBudesonide/Formoterol Fumarate75$18,064
Breo ElliptaFluticasone/Vilanterol42$17,141
Serevent DiskusSalmeterol Xinafoate24$11,981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$338$513,5941,179 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$333$343,913678 claims
AstraZenecaBreztri Aerosphere, Symbicort, Daliresp$138$41,604115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Cayey

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →